News Coverage

The Partnership for Safe Medicines has been publishing information about the counterfeit drug problem around the world for more than a decade. With experts leading the organization and a committed and passionate set of writers and editors, our content is more in-depth than many other sources, which simply copy links to the news from other websites.

FDB to stop increasing counterfeiting of medicines

September 10, 2008

The Food and Drugs Board, FDB, is considering the introduction of a new technology that will detect fake drug products from genuine ones. The technology will indicate codes on the products which will be verified later from the manufacturers. The Acting Deputy Chief Executive of the Board, Rev. Jonathan Martey, announced this in Accra at…

Consumer Protection Group Supports West African Anti-Counterfeit Drug Efforts

September 9, 2008

Partnership for Safe Medicines shares expertise with leaders to combat contraband and counterfeit drugs.

ACCRA, Ghana (Sept. 9, 2008) – To combat the increasing amounts of contraband and counterfeit drugs threatening public health, West African government officials, business leaders, and non-profit organizations gathered today for the Stakeholder Forum on Safe Medicines in Accra, Ghana.  The Partnership for Safe Medicines, a coalition of organizations and individuals dedicated to protecting consumers from counterfeit medicines, helped lead a discussion about how the region can work together to address this important health problem.

Consumer Protection Group Announces Principles for Drug Safety

September 4, 2008

Stopping Counterfeit Drugs at the Source

August 28, 2008

Bryan A. Liang, MD, PhD, JD

Here at the Partnership for Safe Medicines, one of our core principles for drug safety is the need to unify in the fight against counterfeit drugs.  This week, we saw progress.

The Warning Signs of Illegal Online Pharmacies

August 22, 2008

Bryan A. Liang, MD, PhD, JD

Why buy from a store when you can shop on the Internet?  Unfortunately, there are numerous illegal Web sites that will sell you contaminated or counterfeit drugs, unapproved products, the wrong product, or simply take your money and never deliver anything in return.

Out of Time

August 14, 2008

Bryan A. Liang, MD, PhD, JD

Last week, the Food and Drug Administration (FDA) issued a consumer alert warning patients that two Baltimore pharmacies may have received either expired or possibly counterfeit drugs.  Earlier this year, New York Attorney General Andrew M. Cuomo initiated legal action against CVS and Rite Aid pharmacies after a statewide investigation found it had sold expired products, including over-the-counter medications.

An Unexpected Fake in Los Angeles

August 11, 2008

Bryan A. Liang, MD, PhD, JD

Botox treatment is one of the fastest-growing cosmetic procedures on the market today.  With the promise to eliminate wrinkles and fine lines, more and more baby boomers are turning to this product to fight the signs of aging.  However, in addition to battling wrinkles, the makers of Botox now find themselves fighting the illicit business of counterfeit drugs.  

Getting Back to Basics: Use the Standard VIPPS Categories

August 7, 2008

Shabby Standards

July 25, 2008

Bryan A.  Liang, MD, PhD, JD 

Earlier this week, I talked about India's opposition to IMPACT's proposed definition of a counterfeit medicine.  Indian "experts" claimed it would hurt their generic drug industry's exports, and I asked just who these "experts" were protecting if the IMPACT's focus was only non-legitimate producers.  

Defining the Problem

July 22, 2008

Bryan A.  Liang, MD, PhD, JD

Often understanding a problem begins with a definition.  The World Health Assembly, the decision-making body of the World Health Organization (WHO), meets each May to discuss public health issues and determine future WHO policies.  This year, WHO's constituted International Medical Products Anti-Counterfeiting Taskforce (IMPACT) introduced a resolution to update WHO's definition of a counterfeit medicine.  IMPACT proposed changing the definition from "deliberately and fraudulently" mislabeling a medicine's identity and source to the "false representation" of a medical product's identity, history or source.